PMID- 17204867
OWN - NLM
STAT- MEDLINE
DCOM- 20070320
LR  - 20190516
IS  - 1554-8600 (Print)
IS  - 1554-8600 (Linking)
VI  - 3
IP  - 1
DP  - 2007 Jan-Feb
TI  - Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung 
      cancer: analysis of pooled data from three clinical trials.
PG  - 8-13
AB  - We have undertaken the analysis of pooled data from three pilot clinical trials 
      of vaccination with Epidermal Growth Factor (EGF) in patients with advanced non 
      small cell lung cancer (NSCLC), addressing particularly the issue of the 
      relationship between immunization and survival. Eighty-three patients with 
      advanced disease were included in three pilot clinical trials and vaccinated with 
      the EGF Vaccine. The trials were designed to evaluate the immunogenicity and 
      safety of the vaccine using different adjuvants, cyclophosphamide pretreatment or 
      not, and different dosage levels of the vaccine. The vaccine elicited specific 
      anti-EGF antibody titers in 83% of subjects, and 49% developed a good anti-EGF 
      antibody response. The adjuvant, the vaccine dose, and cyclophosphamide 
      pretreatment significantly influenced immunogenicity. Patients that seroconverted 
      survived significantly longer than patients who did not. Good antibody responders 
      survived significantly longer than poor responders. Pooled results from these 
      trials confirm that vaccination with EGF is safe and immunogenic in advanced 
      NSCLC patients. The association between good antibody responses and survival 
      consistently appeared in every single trial independently of the specific trial 
      designs. Although these were small pilot nonrandomized clinical trials not 
      intended to confirm therapeutic effect, the survival of the pooled patient 
      population was statistically greater compared with 163 control patients receiving 
      standard treatment.
FAU - Gonzalez, Gisela
AU  - Gonzalez G
AD  - Center of Molecular Immunology, Havana, Cuba. gisela@cim.sld.cu
FAU - Crombet, Tania
AU  - Crombet T
FAU - Neninger, Elia
AU  - Neninger E
FAU - Viada, Carmen
AU  - Viada C
FAU - Lage, Agustin
AU  - Lage A
LA  - eng
PT  - Journal Article
DEP - 20070122
PL  - United States
TA  - Hum Vaccin
JT  - Human vaccines
JID - 101265291
RN  - 0 (Antibodies)
RN  - 0 (Cancer Vaccines)
RN  - 62229-50-9 (Epidermal Growth Factor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies/blood
MH  - Cancer Vaccines/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Epidermal Growth Factor/*immunology
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - *Vaccination
EDAT- 2007/01/06 09:00
MHDA- 2007/03/21 09:00
CRDT- 2007/01/06 09:00
PHST- 2007/01/06 09:00 [pubmed]
PHST- 2007/03/21 09:00 [medline]
PHST- 2007/01/06 09:00 [entrez]
AID - 3537 [pii]
AID - 10.4161/hv.3.1.3537 [doi]
PST - ppublish
SO  - Hum Vaccin. 2007 Jan-Feb;3(1):8-13. doi: 10.4161/hv.3.1.3537. Epub 2007 Jan 22.